The brain never stops working - and neither do we. At #MTS, our #neurologytranscription services turn complex medical notes into flawless reports with precision, speed, and total #HIPAA compliance. When your work depends on every detail, trust a team that thinks as sharply as you do.
Las Vegas Sands Corp. (NYSE: LVS), and social enterprise Clean the World announced today a first-of-its-kind service in Las Vegas to help homeless people. The Sands Cares Fresh Start Mobile Showers Powered by Clean the World is a traveling hygiene unit that visits locations serving the homeless to provide showers, hygiene supplies and other resources.
LVS contributed more than $200,000 to Sands Cares Fresh Start Mobile Showers, which was unveiled in Las Vegas on July 27, and will offer approximately 250 showers per week. To reach people in need, Clean the World and Las Vegas Sands have partnered with four Las Vegas organizations to offer the service through their homeless community outreach efforts, including WestCare, CARE Complex, Nevada Homeless Alliance and the Nevada Partnership for Homeless Youth. Sands Cares Fresh Start Mobile Showers will provide hygiene services at a partner organization one day each week, where clients can also receive access to a wide array of support, such as emergency shelter, food and clothing supplies, medical care and detoxification services.
To view the multimedia release go to:
https://www.multivu.com/players/English/8061851-las-vegas-sands-clean-the-world-fresh-start-mobile-showers/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
A brief Introduction to the fact that we can use the subconscious mind for healing.
Self improvement follows!
Psycho-neuro-immunology has been proved by medical scientists and is a specific self-improvement technique.
It is the ability to focus the mind in the meditation state then using guided imagery and visualization there is an increase in the T4 cell count which is the fighting cell in the immune system.
This is the deliberate use of the subconscious mind.
Introducing the fact that healing is aided by deliberate use of the subconscious.
Not only will you feel better but real Self Improvement is achieved!
Psycho-neuro-immunology has been proved by medical scientists and is a specific self-improvement technique.
To achieve increasing the fighting cell (T4) in the immune system you use guided imagery and visualization.
The end result is using the subconscious mind deliberately.
A brief Introduction to the fact that we can use the subconscious mind for healing.
Not only will you feel better but real Self Improvement is achieved!
Psycho-neuro-immunology has been proved by medical scientists and is a specific self-improvement technique.
To achieve increasing the fighting cell (T4) in the immune system you use guided imagery and visualization.
This is the deliberate use of the subconscious mind.
Introducing the fact that healing is aided by deliberate use of the subconscious.
Self improvement follows!
Psycho-neuro-immunology has been proved by medical scientists and is a specific self-improvement technique.
The fighting cell in the immune system (the T4 cell) is increased in meditation using guided imagery and visualization.
The end result is using the subconscious mind deliberately.
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Today, Church & Dwight, Co., Inc., the makers of First Response™ pregnancy and ovulation tests, announced the launch of First Response™ Pregnancy PRO Digital Pregnancy Test & App Access – their latest innovation and the first and only Bluetooth Smart-enabled pregnancy test on the market. First Response™ Pregnancy PRO connects to a woman’s smart device through a mobile application. Once synced, the app provides her with pregnancy-related content only available with Pregnancy PRO, and delivers a personalized user experience throughout her entire pregnancy journey.
“We are thrilled to be unveiling the next generation of in-home pregnancy testing on a stage like CES, where so many technological advancements have made their debut,” said Stacey Feldman, Vice President of Marketing, Church & Dwight. “With Pregnancy PRO, we’ve leveraged unique consumer insights to develop a product that not only revolutionizes the pregnancy test category, but more importantly, provides women with the information they need during their journey.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7725251-first-response-pregnancy-pro/
Many women don't realize aging makes heart disease likelier. To combat this problem, teams from Brookdale senior living communities nationwide are fanning out to personally alert women 65 and over to their increased risk and provide resources to fight it. The company hopes to reach 10,000 older women through “10,000 Heart to Hearts,” beginning Feb. 1.
“Cardiac disease kills more women than all cancers combined,” said Brookdale chief medical officer Kevin O'Neil, M.D., F.A.C.P. “On average, women develop heart disease 10 years later than men, with their first heart attack occurring at age 70.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7087732-brookdale-senior-living/
